Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Apr 27, 2023 3:01am
214 Views
Post# 35416265

RE:RE:RE:RE:So they STILL have not applied for BTD???

RE:RE:RE:RE:So they STILL have not applied for BTD???

 

Clarification of previous post highlighted below...


My focus is on the Swimmer's plot...it tells a very interesting story, particularly at the 180 & 270 day marks.

For those patients who maintained a CR throughout the first 270 days & who have also been assessed at 360+ days (total of 11 patients), 9 of 11 (82%) maintained a CR at 360+ days.  The remaining 2 are IR, which would give a total response of 100% for this subgroup. There are 2 other patients who have also maintained a CR throughout the first 270 days who have yet to be assessed at 360 days.  Based on the above trend, there's a good chance those 2 will also be CR at 360 days, or at least IR.  Imo, there's a good chance that of the 27 who have reached the 270 day or longer mark, we could have at least 11 of the 27 (41%) maintain their CR at 450 days.


Of the 15 patients who maintained a CR through 180 days, 13 of 15 (87%) maintained a response at 270+ days, 11 of those 15 (73%) were CR, & only 2 of 15 (13%) were NR for that subgroup.

According to the Swimmer's plot, data seem to be trending swimmingly.  The plot clearly demonstrates that optimization is working & if a patient can remain CR for 270 days, there's a good chance he/she can save a bladder.  All imo.

Additionally, if you dismiss the first 12 undertreated in Study II, our 90 day CR would increase from 54% to 63%. Looking at the 180 day assessment mark, our CR would increase from 62% to 80%.

Keep the data coming : )

<< Previous
Bullboard Posts
Next >>